Sean McCutcheon, Ph.D. - Raymond James & Associates Sean McCutcheon, Ph.D. Raymond James & Associates
Xencor Announces Closing of Research Collaboration and License Agreement with Genentech Read more about Xencor Announces Closing of Research Collaboration and License Agreement with Genentech
Xencor Reports Fourth Quarter and Full Year 2018 Financial Results Read more about Xencor Reports Fourth Quarter and Full Year 2018 Financial Results
Xencor Announces Partial Clinical Hold on Phase 1 Study of XmAb14045 Read more about Xencor Announces Partial Clinical Hold on Phase 1 Study of XmAb14045
Xencor to Host Fourth Quarter and Full Year 2018 Financial Results Webcast and Conference Call on February 25, 2019 Read more about Xencor to Host Fourth Quarter and Full Year 2018 Financial Results Webcast and Conference Call on February 25, 2019
Xencor to Present at Upcoming Investor Conferences Read more about Xencor to Present at Upcoming Investor Conferences
Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech Read more about Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech
Xencor Regains ex-U.S. Commercial Rights to XmAb®13676, CD20 x CD3 Bispecific Antibody Read more about Xencor Regains ex-U.S. Commercial Rights to XmAb®13676, CD20 x CD3 Bispecific Antibody
Xencor Presents Initial Data from Phase 1 Study of XmAb®14045 in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting Read more about Xencor Presents Initial Data from Phase 1 Study of XmAb®14045 in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting
Xencor to Present at 30th Annual Piper Jaffray Healthcare Conference Read more about Xencor to Present at 30th Annual Piper Jaffray Healthcare Conference
